ストックスクリーナーアプリを入手
4.76
2.26%
-0.11
アフターアワーズ：
4.71
-0.05
-1.05%
前日終値:
$4.87
開ける：
$4.89
24時間の取引高:
1.24M
Relative Volume:
0.54
時価総額：
$396.01M
収益：
$14.20M
当期純損益:
$-49.59M
株価収益率:
-5.6505
EPS:
-0.8424
ネットキャッシュフロー:
$-35.25M
1週間 パフォーマンス:
-8.11%
1か月 パフォーマンス:
+15.82%
6か月 パフォーマンス:
+0.21%
1年 パフォーマンス:
+176.74%
1日の値動き範囲:
$4.70
$4.93
1週間の範囲:
$4.60
$5.55
52週間の値動き範囲:
$1.50
$7.07
Opus Genetics Inc Stock (IRD) Company Profile
Compare IRD vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
4.76 | 396.01M | 14.20M | -49.59M | -35.25M | -0.8424 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2026-03-16 | 開始されました | Oppenheimer | Outperform |
| 2026-01-20 | 開始されました | BTIG Research | Buy |
| 2025-12-10 | 開始されました | B. Riley Securities | Buy |
| 2025-11-25 | 開始されました | Piper Sandler | Overweight |
| 2025-10-29 | 開始されました | Wedbush | Outperform |
| 2025-10-16 | 開始されました | Chardan Capital Markets | Buy |
| 2025-04-11 | 開始されました | Craig Hallum | Buy |
| 2024-11-13 | 再開されました | H.C. Wainwright | Buy |
すべてを表示
Opus Genetics Inc (IRD) 最新ニュース
Opus Genetics, Inc.(NasdaqCM: IRD) added to S&P Global BMI Index - marketscreener.com
IRD Should I Buy - Intellectia AI
Opus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified? - Yahoo Finance
Opus Genetics (IRD) CEO exercises 392K-share warrant in cashless deal - stocktitan.net
Form 8K Opus Genetics Inc For: 11 September By Investing.com - Investing.com Nigeria
Opus Genetics Updates Clinical Data Presentation for OPGx-BEST1 Phase 1/2 Trial - kalkinemedia.com
Opus Genetics Gene Therapy OPGx-BEST1 Safe, Shows Improvement in 4 of 5 Patients - Minichart
Opus Genetics Updates OPGx-BEST1 Trial Data and Outlook - TipRanks
Opus Genetics Inc - Reuters
Opus Genetics CEO George Magrath Executes Warrant for 392,157 Shares via Cashless Exercise - Kalkine Media
GOOG: Alphabet IncOrdinary SharesClass C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Opus Genetics (NASDAQ: IRD) Plans Phase 3 Trial for OPGx-BEST1 in 2027 Following Promising Cohort 1 Results - Kalkine Media
Opus BEST1 and done? Gene therapy scores in rare eye diseases - BioWorld News
Opus Genetics: A Resounding Study Success Merits A Higher Valuation (NASDAQ:IRD) - Seeking Alpha
IRD Maintained by Wedbush -- Price Target Raised to $13.00 - GuruFocus
A Quick Look at Today's Ratings for Opus Genetics(IRD.US), With a Forecast Between $10 to $20 - Moomoo
Chardan Raises Price Target on Opus Genetics to $16 From $13, Keeps Buy Rating - marketscreener.com
Opus Genetics Stock Jumps 32% on Five-Patient Eye-Therapy Data—What IRD Must Prove Next - TechStock²
JonesTrading Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Wedbush raises Opus Genetics stock price target on FDA alignment By Investing.com - Investing.com Nigeria
IRD Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
Opus Genetics Shares Jump 30% as Low-Dose Gene Therapy Shows Vision Gains in Retinal Disease Trial - finance.biggo.com
Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy TrialSlideshow - Seeking Alpha
Opus Genetics Shares Rise After Reporting Vision Improvement in Phase 1/2 OPGx-BEST1 Trial - marketscreener.com
IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial - Yahoo Finance
Wedbush raises Opus Genetics stock price target on FDA alignment - Investing.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
IRD: OPGX-BEST1 gene therapy showed robust safety and efficacy, supporting phase III advancement - TradingView
IRD Reiterates by BTIG -- Price Target Maintained at $12.00 - GuruFocus
Why Opus Genetics (IRD) Stock Is Up Today - quiverquant.com
LifeSci Capital Maintains Opus Genetics(IRD.US) With Buy Rating, Raises Target Price to $20 - Moomoo
Opus Genetics Reports Positive Phase 1/2 Data for Gene Therapy OPGx-BEST1 - Minichart
Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says - Benzinga
IRD: OPGX-BEST1 Phase 1/2 trial showed strong efficacy, safety, and FDA alignment for pivotal development - TradingView
Opus Genetics Reports Positive OPGx-BEST1 Phase 1/2 Data, Targets Potential Phase 3 Dosing in 2027 - Yahoo Finance
IRD: OPGX-BEST1 gene therapy showed robust safety and functional gains, supporting pivotal trial advancement - TradingView
Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving High - Benzinga
Opus Genetics Reveals Interim Phase 1/2 BIRD-1 Trial Outcomes for OPGx-BEST1 - Kalkine Media
IRD Stock Jumps As Traders Target Gene Therapy Catalyst - timothysykes.com
IRD Stock Eyes Webcast Catalyst As Gene Therapy Data Nears - StocksToTrade
IRD Maintained by Chardan Capital -- Price Target at $13.00 - GuruFocus
Opus Genetics Reports Positive Phase 1/2 Data for OPGx-BEST1 in BEST1-Related Retinal Disease - Eyewire+
Opus Genetics Reports Vision Improvement in Phase 1/2 OPGx-BEST1 Trial - marketscreener.com
Opus Genetics Reports Positive OPGx-BEST1 Phase 1/2 Data - TipRanks
IRD Looks 1451.8% Overvalued on GF Value™ - GuruFocus
Opus Genetics reports positive low‑dose Cohort 1 OPGx-BEST1 Phase 1/2 data; advances to higher-dose Cohort 2 - TradingView
Opus Genetics Reports Positive Interim Phase 1/2 Results for OPGx-BEST1 in BEST1-Related Retinal Diseases - quiverquant.com
Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027 - Yahoo Finance
Opus Genetics, Inc. (NASDAQ: IRD) Share Price, IRD Stock News, IRD Share Price & Updates - Kalkine
Opus Genetics Director Cam Gallagher Exercises Warrant for 784,314 Shares, Enters 180-Day Lock-Up - Kalkine Media
Opus Genetics (IRD) director adds shares, accepts 180-day lock-up - Stock Titan
Opus Genetics Inc (IRD) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):